BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Company News  |  Deals

Medivir, J&J deal

Medivir partnered with Johnson & Johnson's Janssen Pharmaceutica N.V. unit to discover and develop dengue NS3 protease inhibitors to prevent and treat dengue virus infection. Janssen and Medivir will split research costs equally. The partners each have options to continue funding further development at undisclosed...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >